Mark Emalfarb
Impact in
- Biotechnology top 5%
- Enzyme Production and Characterization
- Biomedical Engineering top 10%
- Biofuel production and bioconversion
- Catalysis for Biomass Conversion
Papers in
-
- SARS-CoV-2 and COVID-19 Research 5
- SARS-CoV-2 detection and testing 2
-
- Enzyme Production and Characterization 2
- Co-authors
- Alexander V. Gusakov (3 shared papers)Arkady P. Sinitsyn (3 shared papers)Richard P. Burlingame (2 shared papers)О. Н. Окунев (2 shared papers)Boris B. Ustinov (1 shared paper)Peter J. Punt (2 shared papers)Rob Joosten (2 shared papers)Jan C. Verdoes (2 shared papers)
- Journals
- Vaccine (2 papers)Vaccines (2 papers)Analytical and Bioanalytical Chemistry (1 paper)Biotechnology and Bioengineering (1 paper)Applied Biochemistry and Biotechnology (1 paper)
- Partner nations
- FinlandNetherlandsUnited States
In The Last Decade
Mark Emalfarb
11 papers receiving 441 citations
Peers
Comparison fields: 5 of 52
- Biotechnology 180
- Biomedical Engineering 294
- Molecular Biology 286
- Biomaterials 43
- Infectious Diseases 46
Countries citing papers authored by Mark Emalfarb
This map shows the geographic impact of Mark Emalfarb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Emalfarb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Emalfarb more than expected).
Fields of papers citing papers by Mark Emalfarb
This network shows the impact of papers produced by Mark Emalfarb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Emalfarb. The network helps show where Mark Emalfarb may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Emalfarb, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 191 | |
| 2 | 2011 | 147 | |
| 3 | 2007 | 38 | |
| 4 | 1998 | 15 | |
| 5 | 2021 | 14 | |
| 6 | 2022 | 14 | |
| 7 | 2022 | 10 | |
| 8 | 2022 | 9 | |
| 9 | 2022 | 8 | |
| 10 | 2024 | 8 | |
| 11 | 2023 | 5 | |
| 12 | 2025 | 0 |
About Mark Emalfarb
Mark Emalfarb is a scholar working on Infectious Diseases, Biotechnology, Molecular Biology, Biomedical Engineering and Physical and Theoretical Chemistry, having authored 12 papers that have together received 459 indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (5 papers), Bacillus and Francisella bacterial research (4 papers), vaccines and immunoinformatics approaches (3 papers), Biofuel production and bioconversion (3 papers), Enzyme Production and Characterization (2 papers), SARS-CoV-2 detection and testing (2 papers), Microbial Metabolic Engineering and Bioproduction (1 paper) and thermodynamics and calorimetric analyses (1 paper). The work is most often cited by research in Biotechnology (180 citations), Biomedical Engineering (294 citations), Molecular Biology (286 citations), Biomaterials (43 citations) and Infectious Diseases (46 citations). Mark Emalfarb has collaborated with scholars based in Finland, Netherlands and United States. Frequent co-authors include Alexander V. Gusakov, Arkady P. Sinitsyn, Richard P. Burlingame, О. Н. Окунев, Boris B. Ustinov, Peter J. Punt, Rob Joosten, Jan C. Verdoes, Jan Wery and Jaap Visser. Their work appears in journals such as Vaccine, Vaccines, Analytical and Bioanalytical Chemistry, Biotechnology and Bioengineering and Applied Biochemistry and Biotechnology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.